Documento descargado de http://http://www.archbronconeumol.org/ el 19/12/2013. Copia para uso personal, se prohíbe la transmisión de este documento por cualquier medio o formato.
J.J. Soler-Catalu˜ na et al / Arch Bronconeumol. 2012;48(9):331–337 14. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ, Isonaka S, Nonikov D, et al. Symptom-based questionnaire for differentiating COPD and asthma. Respiration. 2006;73:296–305. 15. Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27:964–71. 16. Williamson PA, Menzies D, Clearie KL, Vaidyanathan S, Lipworth BJ. Doseresponse for inhaled fluticasone on airway and systemic inflammation in COPD. Eur Respir J. 2011;37:206–9. 17. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:741–50. 18. Van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med. 2002;166:1358–63. 19. Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, et al., COSMIC (COPD, Seretide: a Multi-Center Intervention, Characterization) Study Group. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005;60: 480–7. 20. Cosío BG, Fiorentino F, Scrimini S. EPOC y asma. Arch Bronconeumol. 2010;46 Suppl 8:2–7. 21. Brindicci C, Ito K, Resta O, Pride NB, Barnes PJ, Kharitonov SA. Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J. 2005;26:52–9. 22. Rutgers SR, van der Mark TW, Coers W, Moshage H, Timen W, Kaufmann HF, et al. Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax. 1999;54:566–80. 23. Papi A, Romagnoli M, Baraldo S, Braccioni F, Guzzinati I, Saetta M, et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum
24.
25.
26.
27. 28.
29.
30.
31.
32.
33.
337
eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162:1773–7. Lehtimäki L, Kankaanranta H, Saarelainen S, Annila I, Aine T, Nieminen R, et al. Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. Eur Respir J. 2010;35:72–8. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169:219–29. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15–26. Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thor Soc. 2005;2:334–9. Han MK, Agustí A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes. The future of COPD. Am J Respir Crit Care Med. 2010;182:598–604. Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ, et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12:127, doi:10.1186/1465-9921-12-127. Hospers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP. Histamine airway hyperresponsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet. 2000;356:1313–7. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365:1184–92. Grupo de trabajo de GESEPOC. Hacia un nuevo enfoque en el tratamiento ˜ de la EPOC (GESEPOC). Arch Bronconeumol. de la EPOC. Guía Espanola 2011;47:379–81. Nadeem NJ, Taylor SJ, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD — a systematic review and comment on trial methodology. Respir Res. 2011;12:107.